Synonyms: Brenzavvy® | compound 29 [PMID: 21737266] | EGT-0001442 | EGT-1442 | EGT1442 [6] | THR-1442
bexagliflozin is an approved drug (FDA (2023))
Compound class:
Synthetic organic
Comment: Bexagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor [5], that was developed for its ability to improve control of blood glucose levels for the treatment of type 2 diabetes [1,6]. It is a C-aryl glucoside class molecule.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Bexagliflozin was granted full FDA approval in January 2023 [4]. It was indicated to improve glycemic control in adults with type 2 diabetes, as an adjunct to diet and exercise. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03115112 | Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Phase 3 Interventional | Theracos | 2 | |
NCT02390050 | A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus | Phase 2 Interventional | Theracos | 3 |